Literature DB >> 23037012

Axonal transport and mitochondrial dysfunction in Alzheimer's disease.

Jan Riemer1, Stefan Kins.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia. It is characterized by pathological hallmarks such as extracellular deposits of amyloid plaques as well as intracellular neurofibrillary tangles and a progressive loss of neurons. Additional early pathological features of AD also include a decline in synapse number, axonal dystrophies, mitochondrial hypometabolism and increased oxidative stress. It is assumed that the aggregates of amyloid-β and tau are not the major pathogenic players in AD, but that nonaggregated oligomeric forms of amyloid-β and specific phosphorylated forms of tau cause neurodegeneration. It is tempting to speculate that oligomeric amyloid-β and phosphorylated tau might trigger mitochondrial dysfunction associated with oxidative stress as well as dysfunctions of axonal transport, leading to the loss of spines and neurodegeneration. Here, we summarize the actual data supporting this hypothesis and provide a model how these different mechanisms might be intertwined with each other.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23037012     DOI: 10.1159/000342020

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  15 in total

Review 1.  Mitochondria-associated ER membranes and Alzheimer disease.

Authors:  Estela Area-Gomez; Eric A Schon
Journal:  Curr Opin Genet Dev       Date:  2016-05-25       Impact factor: 5.578

2.  Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice.

Authors:  Dongmei Wang; Bei Wang; Yumei Liu; Xiaohui Dong; Yanwei Su; Sanqiang Li
Journal:  Neurochem Res       Date:  2019-09-30       Impact factor: 3.996

Review 3.  Risky repair: DNA-protein crosslinks formed by mitochondrial base excision DNA repair enzymes acting on free radical lesions.

Authors:  Rachel Audrey Caston; Bruce Demple
Journal:  Free Radic Biol Med       Date:  2016-11-17       Impact factor: 7.376

4.  Synergic Effects of Berberine and Curcumin on Improving Cognitive Function in an Alzheimer's Disease Mouse Model.

Authors:  Lin Lin; Cheng Li; Deyi Zhang; Mingxiang Yuan; Chun-Hai Chen; Maoquan Li
Journal:  Neurochem Res       Date:  2020-02-21       Impact factor: 3.996

5.  8-Oxoguanine accumulation in mitochondrial DNA causes mitochondrial dysfunction and impairs neuritogenesis in cultured adult mouse cortical neurons under oxidative conditions.

Authors:  Julio Leon; Kunihiko Sakumi; Erika Castillo; Zijing Sheng; Sugako Oka; Yusaku Nakabeppu
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

6.  Human mitochondrial transcriptional factor A breaks the mitochondria-mediated vicious cycle in Alzheimer's disease.

Authors:  Sugako Oka; Julio Leon; Kunihiko Sakumi; Tomomi Ide; Dongchon Kang; Frank M LaFerla; Yusaku Nakabeppu
Journal:  Sci Rep       Date:  2016-11-29       Impact factor: 4.379

7.  Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.

Authors:  Angel Agis-Torres; Monica Sölhuber; Maria Fernandez; J M Sanchez-Montero
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

8.  Rescue of tau-induced synaptic transmission pathology by paclitaxel.

Authors:  Hadas Erez; Or A Shemesh; Micha E Spira
Journal:  Front Cell Neurosci       Date:  2014-02-10       Impact factor: 5.505

9.  Upregulation of PGC-1α expression by Alzheimer's disease-associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APP.

Authors:  Ari Robinson; Sven Grösgen; Janine Mett; Valerie C Zimmer; Viola J Haupenthal; Benjamin Hundsdörfer; Christoph P Stahlmann; Yulia Slobodskoy; Ulrike C Müller; Tobias Hartmann; Reuven Stein; Marcus O W Grimm
Journal:  Aging Cell       Date:  2013-12-17       Impact factor: 9.304

Review 10.  Role of berberine in Alzheimer's disease.

Authors:  Zhiyou Cai; Chuanling Wang; Wenming Yang
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.